XenoTherapeutics has been awarded a network of patents integrating lessons learned and inventions derived from our unique, first-mover experience. Under the expedited patent review program, Track One, all of XenoTherapeutics’ patents to date have been awarded by the USPTO in under one year. 

​

​

 

 

 

 

We have been awarded an extensive and integrated family of primary and supporting patents covering our ability to create clinical grade porcine donors, immune-compatible cells, and predictive gene designs:

​

U.S. Patent No. 10,799,614

(Xenotransplantation Products and Methods)

Awarded October 13, 2020

​

Impact: Achieving regulatory approval to create, develop, or enable ANY FDA-acceptable, clinical grade product comprising non-human cells, tissue, or organs, regardless of genetic modification
 

​

​

​

​

​

​

U.S. Patent No. 10,883,084

(Personalized Cells, Tissues, and Organs for Transplantation from a Humanized, Bespoke, Designated-Pathogen Free, Non-Human Donor)

Granted January 5, 2021

​

Impact: The blueprint for creating immune-compatible cells
 

​

​

​

​

​

​

​

 

 

 

 

U.S. Provisional Patent App. No. 63/034,140

(Computational and Predictive Design of Humanized, Bespoke, Non- Human Donor for Transplantation of Personalized Cells, Tissues, and Organs)

Filed June 3, 2020

​

Impact: Predictive algorithm for assessing molecular compatibility between donor and recipient